Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2015

01-09-2015 | Mini Review

Optimal management of non-functioning pituitary adenomas

Authors: Yona Greenman, Naftali Stern

Published in: Endocrine | Issue 1/2015

Login to get access

Abstract

Transsphenoidal surgery is the treatment of choice for large non-functioning pituitary adenomas (NFPA) and symptomatic patients. The therapeutic strategies for the management of NFPA after surgery, i.e., watchful waiting, irradiation, or medical therapy have not been compared by randomized controlled trials. Slow re-growth is common, but the natural history of untreated tumors is variable. Conservative follow-up is associated with progression rates of over 40 %. Radiation is highly effective in preventing residual tumor growth, but has serious long-term side effects. Finally, no medications are currently approved for the treatment of NFPA. In this review, we present our view of the optimal management of these tumors, which includes risk stratification for the identification of high-risk patients suitable for active intervention, leaving low-risk patients for careful monitoring.
Literature
1.
M. Al-Shraim, S.L. Asa, The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 111, 1–7 (2006)CrossRefPubMed
2.
W. Saeger, D.K. Lüdecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156, 203–216 (2007)CrossRefPubMed
3.
S.L. Asa, Practical pituitary pathology. What does the pathologist need to know? Arch. Pathol. Lab. Med. 132, 1231–1240 (2008)PubMed
4.
H. Nishioka, M. Ozgur, S.L. Asa, N. Inoshita, N. Fukuhara, K. Horiguchi, S. Yamada, The crucial role of pituitary transcription factors in the accurate classification of hormone-negative nonfunctioning pituitary adenomas. Endocrine Society Meeting 2014, OR09-2
5.
Y. Greenman, N. Stern, Non-functioning pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23, 625–638 (2009)CrossRefPubMed
6.
M. Losa, P. Mortini, R. Barzaghi, P. Ribotto, M.R. Terreni, S.B. Marzoli, S. Pieralli, M. Giovanelli, Early results of surgery in patients with nonfunctioning pituitary adenomas and analysis of the risk of tumor recurrence. J. Neurosurg. 108, 525–532 (2008)CrossRefPubMed
7.
O.M. Dekkers, A.M. Pereira, J.H.C. Roelfsema, J.H. Voormolen, K.J. Neelis, M.A. Schroijen, J.W. Smit, J.A. Romijn, Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 91, 1796–1801 (2006)CrossRefPubMed
8.
P. Nomikos, C. Ladar, R. Fahlbusch, M. Buchfelder, Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. Acta Neurochir. 146, 27–35 (2004)CrossRefPubMed
9.
Y. Greenman, K. Tordjman, E. Kisch, N. Razon, G. Ouaknine, N. Stern, Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J. Clin. Endocrinol. Metab. 80, 1577–1583 (1995)PubMed
10.
S.M. Webb, M. Rigla, A. Wägner, B. Oliver, F. Bartumeus, Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J. Clin. Endocrinol. Metab. 84, 3696–3700 (1999)CrossRefPubMed
11.
R. Reddy, S. Cudlip, J.V. Byrne, N. Karavitaki, J.A. Wass, Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur. J. Endocrinol. 165, 739–744 (2011)CrossRefPubMed
12.
J. Honneger, U. Ernemann, T. Psaras, B. Will, Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochir. 149, 21–29 (2007)CrossRef
13.
M. Molitch, Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol. Clin. Metab. North Am. 37, 151–171 (2008)CrossRef
14.
N. Karavitaki, K. Collison, J. Halliday, J.V. Byrne, P. Price, S. Cudlip, J.A. Wass, What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin. Endocrinol. 67, 938–943 (2007)CrossRef
15.
J. Feldkamp, R. Santen, E. Harms, A. Aulich, U. Mödder, W.A. Scherbaum, Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas-results of a prospective study. Clin. Endocrinol. 51, 109–113 (1999)CrossRef
16.
K. Arita, A. Tominaga, K. Sugiyama, K. Eguchi, K. Iida, M. Sumida, K. Migita, K. Kurisu, Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J. Neurosurg. 104, 884–891 (2006)CrossRefPubMed
17.
O.M. Dekkers, S. Hammer, R.J.W. de Keizer, F. Roelfsema, P.J. Schutte, J.W. Smit, J.A. Romijn, A.M. Pereira, The natural course of non-functioning pituitary macroadenomas. Eur. J. Endocrinol. 156, 217–224 (2007)CrossRefPubMed
18.
Y. Greenman, G. Ouaknine, I. Veshchev, I.I. Reider-Groswasser, Y. Segev, N. Stern, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. 58, 763–769 (2003)CrossRef
19.
E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernascon, P. Loli, M. Faustini-Fustini, G. Borretta, M. Terzolo, M. Losa, A. Morabito, A. Spada, P. Beck-Peccoz, A.G. Lania, Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. 155, 823–829 (2006)CrossRefPubMed
20.
P. Park, W. Chandler, A. Barkan, J.J. Orrego, J.A. Cowan, K.A. Griffith, C. Tsien, The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55, 100–106 (2004)CrossRefPubMed
21.
E.P. O’Sullivan, C. Woods, N. Glynn, L.A. Behan, R. Crowley, P. O’Kelly, D. Smith, C.J. Thompson, A. Agha, The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin. Endocrinol. 71, 709–714 (2009)CrossRef
22.
N.J.L. Gittoes, A.S. Bates, W. Tse, B. Bullivant, M.C. Sheppard, R.N. Clayton, P.M. Stewart, Radiotherapy for non-functioning pituitary tumours. Clin. Endocrinol. 48, 331–337 (1998)CrossRef
23.
A.A. Kanner, B.W. Corn, Y. Greenman, Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary 12, 15–22 (2009)CrossRefPubMed
24.
E.F. Chang, G. Zada, S. Kim, K.R. Lamborn, A. Quinones-Hinojosa, J.B. Tyrrell, C.B. Wilson, S. Kunwar, Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108, 736–745 (2008)CrossRefPubMed
25.
S. Brochier, F. Galland, M. Kujas, F. Parker, S. Gaillard, C. Raftopoulos, J. Young, O. Alexopoulou, D. Maiter, P. Chanson, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur. J. Endocrinol. 163, 193–200 (2010)CrossRefPubMed
26.
Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96, 333–342 (2012)CrossRefPubMed
27.
K.J. Bradley, J.A. Wass, H.E. Turner, Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumors but do not recur more frequently. Clin. Endocrinol. 58, 59–64 (2003)CrossRef
28.
D. Erickson, B. Scheithauer, J. Atkinson, E. Horvath, K. Kovacs, R.V. Lloyd, W.F. Young Jr, Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin. Endocrinol. 71, 92–99 (2009)CrossRef
29.
G. Kontogeorgos, Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83, 179–188 (2006)CrossRefPubMed
30.
K. Thapar, K. Kovacs, B. Scheithauer, L. Stefaneanu, E. Horvath, P.J. Pernicone, D. Murray, E.R. Laws Jr, Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99–107 (1996)CrossRefPubMed
31.
L. Mastronardi, A. Guiducci, C. Spera, F. Puzzilli, F. Liberati, G. Maira, Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J. Clin. Pathol. 52, 107–111 (1999)PubMedCentralCrossRefPubMed
32.
G. Widhalm, S. Wolfsberger, M. Preusser, I. Fischer, A. Woehrer, J. Wunderer, J.A. Hainfellner, E. Knosp, Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J. Neurosurg. 111, 563–571 (2009)CrossRefPubMed
33.
C. Ramírez, S. Cheng, G. Vargas, S.L. Asa, S. Ezzat, B. González, L. Cabrera, G. Guinto, M. Mercado, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J. Clin. Endocrinol. Metab. 97, 1745–1751 (2012)CrossRefPubMed
34.
M. Losa, A. Franzin, F. Mangili, M.R. Terreni, R. Barzaghi, F. Veglia, P. Mortini, M. Giovanelli, Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long term follow-up studies. Neurosurgery 47, 1313–1319 (2000)CrossRefPubMed
35.
S. Dubois, S. Guyetant, P. Menei, P. Rodien, F. Illouz, B. Vielle, V. Rohmer, Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur. J. Endocrinol. 157, 141–147 (2007)CrossRefPubMed
36.
J. Honegger, C. Prettin, F. Feuerhake, M. Petrick, J. Schulte-Mönting, M. Reincke, Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J. Neurosurg. 99, 674–679 (2003)CrossRefPubMed
37.
R. Gejman, B. Swearingen, E.T. Hedley-Whyte, Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum. Pathol. 38, 758–766 (2008)CrossRef
38.
K.H. Darzy, S.M. Shalet, Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary 8, 203–211 (2005)CrossRefPubMed
39.
G. Minniti, D. Traish, S. Ashley, A. Gonsalves, M. Brada, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenomas: update after an additional 10 years. J. Clin. Endocrinol. Metab. 90, 800–804 (2005)CrossRefPubMed
40.
E.M. Erfurth, B. Bulow, G. Svahn-Tapper, B. Norrving, K. Odh, Z. Mikoczy, J. Björk, L. Hagmar, Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J. Clin. Endocrinol. Metab. 87, 4892–4899 (2002)CrossRefPubMed
41.
J.P. Sheehan, R.M. Starke, D. Mathieu, B. Young, P.K. Sneed, V.L. Chiang, J.Y. Lee, H. Kano, K.J. Park, A. Niranjan, D. Kondziolka, G.H. Barnett, S. Rush, J.G. Golfinos, L.D. Lunsford, Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J. Neurosurg. 119, 446–456 (2013)CrossRefPubMed
42.
Y. Chen, Z.F. Li, F.X. Zhang, J.X. Li, L. Cai, Q.C. Zhuge, Z.B. Wu, Gamma knife surgery for patients with volumetric classification of nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Eur. J. Endocrinol. 169, 487–495 (2013)CrossRefPubMed
43.
D. Van Schaadenburg, F. Roefselma, A.V. Seters, G.J. Vielvoye, Bromocriptine therapy for non-functioning pituitary adenoma. Clin. Endocrinol. 30, 475–484 (1989)CrossRef
44.
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15, 905–915 (2008)CrossRefPubMed
45.
Z. Su, C. Wang, J. Wu, X. Jiang, Y. Chen, Y. Chen, W. Zheng, Q. Zhuge, Z. Wu, Y. Zeng, Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Neurol. Sci. 33, 275–279 (2012)CrossRefPubMed
46.
Y. Greenman, K. Tordjman, E. Osher, I. Veshchev, G. Shenkerman, I.I. Reider-Groswasser, Y. Segev, G. Ouaknine, N. Stern, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. 63, 39–44 (2005)CrossRef
47.
T. Lohmann, C. Trantakis, M. Biesold, S. Prothmann, S. Guenzel, R. Schober, R. Paschke, Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4, 173–178 (2001)CrossRefPubMed
48.
R. Pivonello, C. Matrone, M. Filippela, L.M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, G. Lombardi, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89, 1674–1683 (2004)CrossRefPubMed
49.
W.W. de Herder, A.E. Reijs, R.A. Feelders, M.O. van Aken, E.P. Krenning, H.L. Tanghe, A.J. van der Lely, D.J. Kwekkeboom, Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur. J. Endocrinol. 155, 717–723 (2006)CrossRefPubMed
50.
E.C. Garcia, L.A. Naves, A.O. Silva, L.F. de Castro, L.A. Casulari, M.F. Azevedo, Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16, 189–194 (2013)CrossRefPubMed
51.
R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 356, 39–46 (2007)CrossRefPubMed
52.
P. Lancellotti, E. Livadariu, M. Markov, A.F. Daly, M.C. Burlacu, D. Betea, L. Pierard, A. Beckers, Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol. 159, 1–5 (2008)CrossRefPubMed
53.
M.C. Zatelli, D. Piccin, C. Vignalli, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14, 91–102 (2007)CrossRefPubMed
54.
Y. Greenman, S. Melmed, Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79, 724–729 (1994)PubMed
55.
G. Raverot, N. Sturm, F. de Fraipont, M. Muller, S. Salenave, P. Caron, O. Chabre, P. Chanson, C. Cortet-Rudelli, R. Assaker, H. Dufour, S. Gaillard, P. François, E. Jouanneau, J.G. Passagia, M. Bernier, A. Cornélius, D. Figarella-Branger, J. Trouillas, F. Borson-Chazot, T. Brue, Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592–4599 (2010)CrossRefPubMed
56.
A.I. McCormack, J.A. Wass, A.B. Grossman, Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur. J. Clin. Invest. 41, 1133–1148 (2011)CrossRefPubMed
57.
G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. 76, 769–775 (2012)CrossRef
58.
T. Hirohata, K. Asano, Y. Ogawa, S. Takano, K. Amano, O. Isozaki, Y. Iwai, K. Sakata, N. Fukuhara, H. Nishioka, S. Yamada, S. Fujio, K. Arita, K. Takano, A. Tominaga, N. Hizuka, H. Ikeda, R.Y. Osamura, S. Tahara, Y. Ishii, T. Kawamata, A. Shimatsu, A. Teramoto, A. Matsuno, DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J. Clin. Endocrinol. Metab. 98, 1130–1136 (2013)CrossRefPubMed
Metadata
Title
Optimal management of non-functioning pituitary adenomas
Authors
Yona Greenman
Naftali Stern
Publication date
01-09-2015
Publisher
Springer US
Published in
Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0685-8

Other articles of this Issue 1/2015

Endocrine 1/2015 Go to the issue

Position statement/Guideline

The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)

Original Article

Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease

Review

Phosphodiesterase 8B and cyclic AMP signaling in the adrenal cortex

Review

Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome

Original Article

Immunoregulatory molecules in patients with gestational diabetes mellitus

Editorial

Management of hypogonadism: is there a role for salivary testosterone
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits